Laval University and GlaxoSmithKline have shown that peripheral administration of the adjuvant MPL can help treat Alzheimer's disease in mice. Although the findings point to a potential immunomodulatory approach for addressing the neurodegenerative disease, the pharma is now focusing on elucidating the mechanism before advancing the program.